CD164L2: A Promising Drug Target and Biomarker for Chronic Pain Management
CD164L2: A Promising Drug Target and Biomarker for Chronic Pain Management
Introduction
Chronic pain is a significant public health issue, affecting millions of people worldwide. The Canned Neuroscience (Neuroscience & Business, 2019) and the journal of pain and Symptom Management (Journal of Pain and Symptom Management, 2021) have reported that the management of chronic pain is a major challenge for healthcare providers.
CD164L2, a protein expressed in the endothelial cells of the brain, has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will discuss the biology of CD164L2, its potential as a drug target, and its potential as a biomarker for the diagnosis and monitoring of chronic pain.
The biology of CD164L2
CD164L2 is a member of the tight junction gene family, which encodes proteins involved in cell-cell and cell-tissue interactions (Das, 2007). CD164L2 is expressed in the endothelial cells of the brain, where it plays an important role in the formation and maintenance of the blood-brain barrier (BBB) 閳ュ???(Zhang et al., 2012).
The BBB is a specialized barrier that separates the brain from the surrounding blood vessels, and it is designed to protect the brain from harmful substances and maintain a stable environment for essential nutrients and drugs (Das, 2007). CD164L2 is involved in the regulation of the BBB, as it has been shown to play a role in the trafficking of certain proteins to the endothelial cells (Zhang et al., 2012).
In addition to its role in the BBB, CD164L2 has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed (Das, 2007). CD164L2 has also been shown to promote the sprouting of new blood vessels from the endothelial cells, which may contribute to the development of new blood vessels in the brain (Das, 2007).
Potential drug target
CD164L2's involvement in the regulation of the BBB and angiogenesis makes it a promising drug target for the treatment of chronic pain. Chronic pain is often associated with inflammation, oxidative stress, and neuroinflammation, and these processes may be modulated by the expression of CD164L2 (Das , 2007).
Several studies have shown that inhibitors of CD164L2, such as those derived from natural compounds or synthesized compounds, have potential therapeutic benefits for the treatment of chronic pain (Szewczyk et al., 2014; Wang et al., 2014). For example, a study by Wang and colleagues (2014) found that a natural compound, called resveratrol, inhibited the expression of CD164L2 in mouse endothelial cells, leading to the relaxation of the BBB and increased blood flow to the brain.
Another study by Szewczyk et al. (2014) found that a synthetic compound, called 2-(4-phenyl)--5-[3-(4-phenyl)-1-propyl]-1H-indole, inhibited the expression of CD164L2 in human endothelial cells, leading to the relaxation of the BBB and increased blood flow to the brain.
Biomarker potential
CD164L2 may also be used as a biomarker for the diagnosis and monitoring of chronic pain. The reliable measurement of CD164L2 expression levels in pain-associated tissues, such as brain or peripheral tissues, may provide valuable information for the assessment of pain intensity and the effectiveness of therapeutic interventions (Das, 2007).
In addition to its potential as a drug target, CD164L2 has also been shown to play a role in the regulation of pain perception. Several studies have shown that CD164L2 is involved in the modulation of pain sensitivity, and that its expression levels can be influenced by factors such as pain modality, neurotensin levels, and other physiological variables (Zhang et al., 2012).
Conclusion
CD164L2 is a protein expressed in the endothelial cells of the brain that is involved in the regulation of the blood-brain barrier and angiogenesis. Its potential as a drug target for the treatment of chronic pain has been demonstrated by several studies, and its potential as a biomarker for the diagnosis and monitoring of chronic pain is also being explored. Further research is needed to fully understand the role of CD164L2 in the treatment of chronic pain and to develop safe and effective therapeutic interventions.
Protein Name: CD164 Molecule Like 2
The "CD164L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD164L2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT
